The development of novel medications for alcohol use disorder (AUD) is a NIAAA research priority. The Clinical Research Project is designed to translate the discoveries of preclinical TSRI-ARC investigators for potential therapeutic use using proof-of-concept human laboratory testing. This component has 2-way interactions with all the individual Research Projects of the ARC and the Animal Models Core. The animal work will validate the choices of a ?next generation? selective glucocorticoid receptor antagonist drug and a drug that is hypothesized to restore microtubule homeostasis, and the Clinical Research Project will validate these targets as potential therapeutics treatment of AUD. Should either target ultimately prove to be untenable to pursue human studies, other systems under study by the TSRI-ARC may be viable, such as specific glutamate, serotonin, or hypocretin targets. Drugs identified for human study will either be FDA-approved or available under an IND and will be selected by Dr. Mason based on scientific prioritization by the TSRI-ARC Steering Committee, Program Advisory Committee, and safety considerations. Drugs will be tested in a highly standardized, reliable, and valid human laboratory model informing the 3 stages of the addiction cycle: withdrawal/negative affect, preoccupation/anticipation, and binge/intoxication. Human laboratory results will serve as an analogue for drinking outcomes of clinical treatment trials. Subjects for each study will be 50 non- treatment-seeking male and female paid volunteers who meet DSM-5 criteria for AUD of ? moderate severity (AUD-MS). Studies are randomized, double-blind, and placebo-controlled. The treatment duration is at least 1- week and guided by drug pharmacokinetics. The primary endpoint is craving scores in response to in vivo alcohol cues presented in the laboratory with confirmatory physiological outcomes and naturalistic measures of drinking, negative affect, craving, sleep and executive function.
Specific Aim 1 : To evaluate TSRI-ARC drug candidates in paid non-treatment-seeking volunteers with current AUD-MS using the human lab model of the addiction cycle.
Specific Aim 2 : To identify potential biomarkers of clinical outcomes (e.g., peripheral markers of stress, including hypothalamic-pituitary-adrenal axis, serotonin, hypocretin, and measures of microtubule homeostasis) and drug plasma concentration. Safety Aim 3: To evaluate the safety and tolerability of TSRI- ARC drug candidates in subjects with AUD-MS as assessed by significant changes from baseline in EKG, routine blood and urine biochemistry, vital signs, physical exam, and subjective complaints relative to placebo. Hypothesis: The overall hypothesis under test is that, relative to placebo, novel drug candidates identified by the TSRI-ARC will significantly attenuate responsivity to alcohol cues in the human lab model and reduce drinking, craving, negative affect, insomnia and executive function deficits during treatment and 1-month follow-up. Interpretation of Results: Positive findings will provide clinical validation of stress targets identified by the TSRI-ARC and provide a rational basis for later phase testing of candidate drugs for AUD-MS.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Comprehensive Center (P60)
Project #
5P60AA006420-38
Application #
10075859
Study Section
Special Emphasis Panel (ZAA1)
Project Start
1983-12-01
Project End
2022-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Ehlers, Cindy L; Wills, Derek; Gilder, David A (2018) A history of binge drinking during adolescence is associated with poorer sleep quality in young adult Mexican Americans and American Indians. Psychopharmacology (Berl) 235:1775-1782
Pavon, Francisco J; Serrano, Antonia; Sidhpura, Nimish et al. (2018) Fatty acid amide hydrolase (FAAH) inactivation confers enhanced sensitivity to nicotine-induced dopamine release in the mouse nucleus accumbens. Addict Biol 23:723-734
Logrip, Marian L; Walker, John R; Ayanwuyi, Lydia O et al. (2018) Evaluation of Alcohol Preference and Drinking in msP Rats Bearing a Crhr1 Promoter Polymorphism. Front Psychiatry 9:28
Serrano, Antonia; Pavon, Francisco J; Buczynski, Matthew W et al. (2018) Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake. Neuropsychopharmacology 43:1840-1850
Spierling, Samantha R; Kreisler, Alison D; Williams, Casey A et al. (2018) Intermittent, extended access to preferred food leads to escalated food reinforcement and cyclic whole-body metabolism in rats: Sex differences and individual vulnerability. Physiol Behav 192:3-16
Blasio, Angelo; Wang, Jingyi; Wang, Dan et al. (2018) Novel Small-Molecule Inhibitors of Protein Kinase C Epsilon Reduce Ethanol Consumption in Mice. Biol Psychiatry 84:193-201
Kirson, Dean; Oleata, Christopher Shaun; Parsons, Loren Howell et al. (2018) CB1 and ethanol effects on glutamatergic transmission in the central amygdala of male and female msP and Wistar rats. Addict Biol 23:676-688
Matzeu, Alessandra; Kallupi, Marsida; George, Olivier et al. (2018) Dynorphin Counteracts Orexin in the Paraventricular Nucleus of the Thalamus: Cellular and Behavioral Evidence. Neuropsychopharmacology 43:1010-1020
de Guglielmo, Giordano; Conlisk, Dana E; Barkley-Levenson, Amanda M et al. (2018) Inhibition of Glyoxalase 1 reduces alcohol self-administration in dependent and nondependent rats. Pharmacol Biochem Behav 167:36-41
Matzeu, Alessandra; Terenius, Lars; Martin-Fardon, Remi (2018) Exploring Sex Differences in the Attenuation of Ethanol Drinking by Naltrexone in Dependent Rats During Early and Protracted Abstinence. Alcohol Clin Exp Res 42:2466-2478

Showing the most recent 10 out of 211 publications